Osteopore (ASX:OSX) launched a clinical trial with Princess Alexandra Hospital for the reconstruction of jawbones in at least 10 adult patients, with the single-arm feasibility trial will be conducted in Australia, according to a Wednesday ASX filing.
It plans to determine the safety and tolerability of polycaprolactone-tricalcium phosphate scaffolds with a vascularized corticoperiosteal tissue transfer. The technique, applied with the polycaprolactone-tricalcium phosphate scaffolds, was previously successfully employed in previous cranial and long-bone reconstruction trials.
Patient recruitment for the maxillomandibular reconstruction trial is expected by 2028, and patient follow-up is expected to be 36 months post-surgery.
The Human Research and Ethics Committee at Metro South Health provided clearance, while the firm expects clearance from the Research Governance Office.
Its shares jumped 7% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。